PURPOSECannabis has been legalized across multiple states over the past decade; however, its use among cancer survivors ...

Cancer incidence increases with age, especially in lung cancer, with a median age of diagnosis at 70 years. 4, 5 However, a subset of this population is diagnosed at a very young age. In the absence ...

JCO invites you to enter our first Art of Oncology Narrative Medicine Contest for early career oncologists. Entries will be accepted through August 31, 2025. Finalists will be judged by a panel of ...

Thromboembolic adverse events are preventable. In a large randomized controlled trial (RCT) of primary thromboprophylaxis with rivaroxaban 10 mg once daily (v placebo) in ambulatory patients with ...

Patients with pretreated R/M CC were randomly assigned to receive camrelizumab (200 mg intravenously once every 3 weeks) plus famitinib (20 mg orally once daily), camrelizumab, or investigator's ...

The excellent cure rates documented in clinical trials today constitute a very high bar for attempts to de-escalate therapy for early-stage breast cancer (EBC). Moreover, any therapy de-escalation ...

Patritumab deruxtecan (HER3-DXd; MK-1022) is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody to HER3 (patritumab) covalently linked ...

During 2009-2015, 1,094 patients were registered. After excluding ineligible patients, 302 and 753 patients were included in the SURF-RCT (surgery, n = 150; RFA, n = 152) and SURF-Cohort trial ...

We conducted a multisite randomized trial among adults undergoing autologous or allogeneic HSCT at three academic institutions. Patients were randomly assigned to an inpatient palliative care (PC) ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Effective treatment options, such as resection, liver transplantation, and ablation, exist for early-stage HCC, and patients with locally advanced disease may be candidates for liver-directed ...

Oxaliplatin-based adjuvant chemotherapy is used for stage III colon cancer, but may induce disabling neurotoxicity. We previously showed that the incidence of oxaliplatin-induced peripheral ...